Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma

Table 1 Clinical characteristics of five neuroendocrine carcinoma patients with a history of radical radiotherapy for nasopharyngeal carcinoma

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age	59	67	50	56	49
Gender	Male	Male	Male	Male	Male
Year diagnosed NPC	2008	2007	2005	2010	2002
NPC stage	T3N2M0	T3N1M0	T3N0M0	T2N0M0	*
Treatment of NPC
RT	2008	2007	2005	2010	2002
	70 Gy/35F	70 Gy/35F	Radical RT	70 Gy/35F	Yes*
	2D	2D	2D	2D	2D
CT	DDP	DDP	DDP	DDP	Yes*
Date diagnosed NEC	2018/09/20	2020/03/09	2019/01/31	2020/04/29	2020/09/01
Sites of NEC	Left nasal cavity	Right hard palate	Left nasal cavity	Right nasal cavity-skull base	Left ethmoidal sinus
Treatment of NEC
ST	–	2020/03/06	2019/02/19	2020/04/23	2020/08/24
RT	GTV 70 Gy/33F	–	GTV 66 Gy/30F	GTV 64 Gy/30F	–
	2018/10/23	–	2019/04/08	2020/05/25	–
	IMRT	–	IMRT	IMRT	–
CT	VP	VP	VP	VP	GP
PFS	6 m	3 m	4 m	Censored	Censored
OS	9 m	3 m	9 m	Alive	Alive

NEC, neuroendocrine carcinoma; NPC, nasopharyngeal carcinoma; OS, overall survival; IMRT, intensity modulated radiation therapy; RT, radiotherapy; CT, chemotherapy; ST, surgery therapy; GP, gemcitabine + DDP (cisplatin); VP, VP16 (etoposide) + DDP (cisplatin); 2D, two-dimensional radiotherapy
–, not performed; *, no exact details

ISSN: 1748-717X